🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

With senolytics dead & epigenetic reprogramming near the end of life, geroscience needs to come up with the next fad. A fresh new story of rejuvenation to milk the next bunch of billionaires not wanting to die. What will it be? I don't see anything yet.

Quick ARTAN Biotechnology update. Our CRO is shipping out RNA from various tissues so we can look at where our Artan-102 is going after delivery. On the manufacturing side, Lonza shipped formulations for potency tests in our functional assay. Hope to have data to report in the next 2-3

My brain completely shuts down when someone responds with a Calendly link. Can't do it.

As the new Head of DeSci at Sei Development Foundation I’m excited to share my vision for DeSci V2. The future, however, will be written by you: the builders and community members. The infrastructure is ready. The capital is committed. Now it’s time to buidl 🧬 blog.sei.io/what-is-desci-…

🤖 AI is reshaping the world our kids will inherit. We need bold ideas—and real action. ✅ Excited to speak at the Common Sense Media #CSSummit25 in SF 3/24-25 on digital well-being, education, and AI. 🧭 I'll share highlights from the Stanford GenAI Psychological Safety Plan

Honored to be recognized tomorrow as Wake Forest CTSI Wake Forest University School of Medicine 2024 Research Award in Mid-Career Basic/Translational category. Congrats to all the winners this year Jared Weis Kunal Kadakia Sarah Birken Mohamed E. Salem, MD, FASCO Andrew Michael South, MD, MS Heidi Klepin

x.com/i/article/1908…

Two weeks from now, we will be converging on Washington to brief members of Congress and staff on aging biology and the importance of it towards achieving a healthy America. I am looking forward to sharing this opportunity with some of the most thoughtful minds in the field.

Drug launches are hard, especially for companies with no experience. Yet its becoming more common First timers underperform expectations vs experienced peers ~75% vs ~55% of the time McKinsey & Company correlates this to greater & earlier commercial investment from exper. Do you agree?

Great talk by Todd White about The Thalion Initiative (US)! As Managing Director of The Thalion Initiative, he’s helping advance some of the most promising work in aging research by supporting organizations and initiatives with real impact.

Recent interview regarding our Cell Reports Medicine manuscript Wake Forest University School of Medicine Wake Forest Baptist - Comprehensive Cancer Center drugdiscoverynews.com/a-healthy-brea…

I’m never deleting this app.

Part of the MOA of ARTAN Biotechnology / VitaRNA. Look forward to continue the progress supported by the DeSci community! Find out more at vitarna.xyz. VitaDAO 💛 Bio Protocol Molecule

We’re excited to announce a major milestone at Rubedo Life Sciences: our first patients have been dosed! With this, Rubedo officially enters the clinic as a clinical-stage longevity biotech. businesswire.com/news/home/2025…

Taurine, a darling of longevity seekers, is found to be unreliable biomarker for aging Study shows levels of the amino acid rise rather than fall over time, confounding the goal of dietary supplements statnews.com/2025/06/05/tau…

This is rampant in DeSci and the Longevity space. I hope folks stay disciplined and discerning. How about we promote and support science-grounded approaches that have transformative potential…like ARTAN Biotechnology / VitaRNA. We’ll continue to do our part!

Paul Kohlhaas bio/acc Andreas Melhede bio/acc I’d love to hear your thoughts about vitarna. We’re trying to move forward after an unsuccessful raise in the spring. Hard to move forward without funding. May need to go the traditional route which feels like it defeats the purpose of the movement.

During my talk I specifically called out these gene therapy clinics and they way they are operating. I suggested one improvement would be an independent body that collects and aggregates the data on both efficacy and adverse events. Afterward folks from the conference shared some

What doesn’t work in longevity medicine today? Direct to consumer biological age and microbiome tests. Why do I say that? (1) The don’t measure what they claim to measure (2) They provide no information on precision or accuracy (3) There is no industry quality control (4) There

Keep an eye out on Artan-102 and $vitarna! Latest non-con can be found here: molecule.xyz/ipts/VITARNA